PLK1 and neoplasm: In preclinical models the anti-tumor activity of PLK1 inhibition through RNA interference have been demonstrated [126,127,128], thus several clinical trials based on the pharmaceutical TKM-080301 were carried out by Tekmira Pharmaceuticals.